Objective: Soy isoflavones are commonly used to alleviate menopause-related symptoms. Postmenopausal women are at increased risk for hypothyroidism, and there are concerns that isoflavones may be detrimental to thyroid health. The aim of this study was to examine the effects of soy protein and isoflavones on thyroid function and the relationship between thyroid function and ovarian function.
M enopausal transition is often accompanied by lifedisrupting symptoms such as hot flashes and vaginal dryness, as well as increased risk of osteoporosis, cardiovascular disease, and cognitive decline. Although estrogen replacement through hormone therapy (HT) is the most effective method for treating menopausal symptoms, 1 results of the Women's Health Initiative 2 and the Heart and Estrogen/progestin Replacement Study 3, 4 suggest that the health risks associated with HT may outweigh the benefits. These observations have stimulated the use of alternatives to HT, including soy isoflavones, which are plant-derived compounds with estrogen-like activity. In humans and animals, isoflavones bind to estrogen receptors (ERs). They have a greater affinity for ER-A than for ER-> and can exert both estrogen-agonist and estrogen-antagonist properties. Supplements commonly contain soy protein, which is a rich source of isoflavones (specifically genistein, daidzein, and glycitein). 5 The popularity of soy isoflavones in postmenopausal women results from an apparent absence of adverse effects. However, soy isoflavones may negatively affect thyroid function. 6 Thyroid function relies on the release of thyroidstimulating hormone (TSH) from the anterior pituitary gland in response to circulating triiodothyronine (T 3 ) and thyroxine (T 4 ) levels. TSH regulates thyroid peroxidase (TPO) activity and iodine uptake by the thyroid. TPO couples iodine to thyroglobulin to yield T 3 or T 4 . In vitro, soy isoflavones inhibit TPO, but this inhibition can be prevented by iodine supplementation. 7 The thyroid predominantly releases T 4 , which is converted by peripheral deiodinases (types I and II) into the more active T 3 .
Soy was originally thought to be goitrogenic and to cause hypothyroidism. 7 In humans, rats, and monkeys, hypothyroidism has been associated with menstrual irregularities and infertility. 8<11 In postmenopausal women, the prevalence of hypothyroidism reaches 10% 12 and may exacerbate disorders associated with menopause such as osteoporosis, cardiovascular disease, and neuropsychiatric disease. 13 Although mechanisms through which soy or soy isoflavones could interfere with thyroid function have been identified, reported effects have been inconsistent. Most human studies, including studies on both men and women, have found no significant effect of soy isoflavones on adult thyroid function. 6 These studies were all short-term and cross-sectional, and used variable doses of isolated soy protein (SOY) supplementation. Persky et al 14 found no significant effect of SOY on thyroid hormone concentrations after 3 and 6 months in women aged 49 to 83 years. This study did not control for individual differences in age, ethnicity, 15 body mass index, 16 smoking status, 17 diet, 18 and underlying disease, 19 which may have confounded the results. However, Duncan et al 20 studied a far more select and homogeneous sample and also found no thyroidal effects on postmenopausal women after 3 months of SOY treatment. Neither study controlled for the effects of energy intake, circadian rhythm, and seasonality, all of which may affect thyroid function. 21, 22 Studies using animal models can control for many of the environmental variables thought to influence thyroid function.
Controlled experiments with rodents demonstrate that isoflavones induce increases in serum T 4 concentration. 23, 24 However, rodent thyroid function and regulation differ from those in primates. 25 The main thyroid hormone carrier protein in primates, thyroidbinding globulin (TBG), is not present in rodents. Isoflavone metabolism also differs markedly between rodents and humans. 26 Accordingly, we used nonhuman primates (NHPs) in a long-term, controlled, randomized study to determine the effects of dietary soy on thyroid function and the relationship between thyroid function and ovarian function.
METHODS

Animals
Eighty-two adult (based on radiographic evidence of complete epiphysial closure at the distal radius, ulna, and proximal tibia) female cynomolgus monkeys (Macaca fascicularis) were imported from Indonesia and housed in social groups (five to six animals each) indoors on a 12-hour light/12-hour dark cycle. All animal manipulations were performed according to the guidelines of state and federal laws, the US Department of Health and Human Services, and the Animal Care and Use Committee of Wake Forest University School of Medicine. Wake Forest University is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care.
Study design Baseline phase
During an 8-month baseline phase, monkeys were fed casein-lactalbumin (CL) diet (19% of calories from protein, 35% of calories from fat, and 46% of calories from carbohydrate; cholesterol 0.28 mg/kcal, which was reduced to 0.20 mg/kcal later in the study; Fig. 1 ). This diet was designed to simulate the composition of a typical American diet, which is thought to increase the risk of chronic diseases. 27, 28 Preovariectomy treatment phase Social groups of monkeys were assigned to one of two treatment conditions for 34 months. Because individual differences in plasma cholesterol responses to dietary fat and cholesterol could influence outcomes, the two treatment groups were matched on total serum cholesterol and highdensity lipoprotein cholesterol responses to the baseline diet. The two treatment groups differed only in the main protein source: SOY (n = 41; SUPRO; Solae Corp, St Louis, MO) or CL (n = 41; the same diet consumed by all animals during the pretreatment phase). In addition, approximately 20% of protein fed in each diet was derived from wheat flour.
Postovariectomy treatment phase
After 34 months, surgical menopause was induced in all animals through ovariectomy via laparotomy. Half of the monkeys from each diet treatment group continued to consume their pretreatment phase diet (either SOY [n = 19] or CL [n = 21]) for an additional 34 months. The remainder of the FIG. 1. Experimental protocol. Morning blood samples were obtained for thyroid hormone (TH; thyroxine, triiodothyronine, and thyroid-stimulating hormone) determination 3 weeks after onset of study (baseline phase), 30 months after onset of treatment (pre-OVX treatment phase), and 9 months after ovariectomy (post-OVX treatment phase). During the last 6 months of the baseline phase, awake blood samples were obtained to determine the peak luteal phase progesterone (P 4 ) concentration in a subset of 55 animals. Circulating isoflavone (I) concentrations were sampled 7 and 19 months after the initiation of the pre-OVX treatment phase and were repeated 12 and 24 months after the initiation of the post-OVX treatment phase. CL, caseinlactalbumin; SOY, isolated soy protein; OVX, ovariectomy. animals did not continue their diets and thus were not considered further.
Diet
SOY diet contained 1.88 mg total isoflavone/g protein and was fed at a concentration designed to provide the equivalent of a woman's daily consumption of approximately 140 mg of aglycone units of isoflavone, assuming a daily intake of about 1,800 kcal (ie, isoflavone 0.0775 mg/kcal). Monkeys received 120 kcal diet/kg body weight or approximately 9.3 mg isoflavone/kg body weight. Caloric adjustment of dose reflects higher metabolic rates in monkeys compared with humans. The diets were matched in macronutrients (19% of calories from protein, 35% of calories from fat, and 46% of calories from carbohydrate), cholesterol (0.20 mg/kcal), and vitamin/ mineral content. 29 
Ovarian function
The methods used to collect ovarian function data have been previously described. 30 Briefly, monkeys were trained to present for daily blood sampling without anesthesia during the last 6 months of the baseline phase. Owing to the extensive training required for awake blood sampling, ovarian function was assessed in a subset (n = 55) of animals (29 of which were later assigned to the SOY treatment group and 26 of which were later assigned to the CL treatment group). Blood samples were assessed for progesterone concentrations, and the two highest progesterone concentrations from the luteal phase of each cycle were averaged (mean peak progesterone for each cycle). These values were averaged across all cycles to provide a mean progesterone value for each animal.
Isoflavone concentration
Seven and 19 months after the initiation of the preovariectomy (pre-OVX) treatment phase, blood samples were collected from all animals after ketamine sedation (10-15 mg/kg) to determine circulating isoflavone levels. 30 Animals were fed in the morning and sedated for blood collection 4 hours after feeding. Blood was immediately processed, frozen, and protected from light until analysis. Serum isoflavones from soy protein (genistein, daidzein, and glycitein) and a daidzein metabolite (equol) were analyzed by liquid chromatography photodiode array tandem mass spectrometry. Isoflavone assessments were repeated 12 and 24 months after the initiation of the postovariectomy (post-OVX) treatment phase.
Thyroid hormones
Blood samples were taken between 8:00 and 10:30 AM after ketamine sedation (10-15 mg/kg), 3 weeks after the onset of the study (baseline phase), 30 months after the onset of treatment (pre-OVX treatment phase), and 9 months after ovariectomy (post-OVX treatment phase). After blood clotting, all samples were centrifuged, and serum was drawn off, aliquoted, and frozen at j70-C until samples from all study phases were ready for analysis.
Serum levels of total T 3 , free T 4 , and TSH were determined by radioimmunoassay (T 3 and T 4 ) and immunoradiometric assay (TSH) kits (Diagnostic Product Corp, Los Angeles, CA) at the Yerkes Biomarker Laboratory (Atlanta, GA). The interassay variations for total T 3 were 8.96% at 78.41 ng/dL, 11.17% at 150.91 ng/dL, and 4.57% at 291.51 ng/dL. The intra-assay variation for total T 3 was 2.06%. The interassay variations for free T 4 were 2.0% at 0.40 ng/dL, 5.6% at 1.21 ng/dL, and 6.9% at 2.08 ng/dL. The intra-assay variation for free T 4 was 12.78% at 1.82 ng/dL. The interassay variations were 5.9% at 0.33 KIU/mL, 3.4% at 3.50 KIU/mL, and 5.5% at 27.0 KIU/mL. The intra-assay variations for TSH were 5.8% at 0.36 KIU/mL, 2.5% at 3.83 KIU/mL, and 2.3% at 29.20 KIU/mL.
Statistical analysis
Baseline characteristics of the population (body weight, T 3 , T 4 , TSH, and progesterone) were compared between treatment groups using Student's t test. The effect of treatment on thyroid hormones was analyzed with 2 (treatment phase)YÂY2 (SOY and CL) mixed-model analysis of variance (ANOVA) and analysis of covariance (ANCOVA) using baseline or pre-OVX treatment phase values as covariates. Baseline thyroid function measurements were not obtained for three animals that were later assigned to the CL condition. Correlations between T 3 , T 4 , and TSH and progesterone were assessed by r. Statistical significance was set to P G 0.05 (two-tailed), and all results were presented as mean (SEM). Statistical analysis was performed using STATISTICA 10.0 for Windows (StatSoft Inc, Tulsa, OK).
RESULTS
Baseline characteristics of the study population
During the baseline phase, there were no significant differences in body weight, T 3 , T 4 , and progesterone among animals later assigned to either CL or SOY; however, TSH was higher in animals later assigned to CL, compared with the SOY condition ( Table 1) . Baseline phase measures obtained from all animals demonstrated that the mean progesterone concentrations correlated with T 3 (r = +0.41, P G 0.01; Fig. 2 ) but not with T 4 (r = +0.11, P = 0.41) or TSH (r = +0.01, P = 0.94).
Isoflavones
Total serum isoflavones were present in only trace amounts during the baseline phase and did not differ significantly between treatment groups ( Table 2) . 30 Total serum isoflavones, genistein, daidzein, and equol were significantly elevated in the SOY group during both treatment phases ( Table 2) .
Diet effects on thyroid function in reproductively intact monkeys
The mean (SEM) thyroid hormone levels and body weight during the treatment phases are presented in Table 3 . Repeatedmeasures ANOVA comparing baseline phase and pre-OVX treatment phase indicated no significant differences in body weight. Repeated-measures ANOVA comparing baseline phase and pre-OVX treatment phase values indicated a significant time-by-diet interaction for T 3 (F 1,80 = 7.01, P = 0.01; Fig. 3 ) but not for T 4 (F 1,80 = 2.73, P = 0.10; data not shown). Although nonsignificant, differences in baseline means for animals later assigned to CL and SOY suggested the use of ANCOVA to adjust for data collected during baseline. Covariance of baseline values revealed a significant increase in T 3 , but not in T 4 , after SOY treatment (T 3 : F 1,79 = 6.23, P = 0.01; Fig. 3 ; T 4 : F 1,79 = 1.71, P = 0.19).
A repeated-measures ANOVA comparing baseline phase and pre-OVX treatment phase values indicated that TSH increased significantly across time (F 1,80 = 44.58, P G 0.01) but was not affected by diet (F 1,80 = 1.80, P = 0.18; data not shown). Moreover, the time-by-diet interaction was not significant (F 1,80 = 2.76, P = 0.20). Because TSH assessed during baseline differed between animals later assigned to the CL and SOY conditions, ANCOVA using baseline phase values as covariate was again performed; here, there were no significant differences between dietary conditions (F 1,79 = 1.69, P = 0.20).
Diet effects on thyroid function in ovariectomized monkeys
Repeated-measures ANOVA comparing pre-OVX treatment phase and post-OVX treatment phase values revealed a significant ovariectomy-by-diet interaction for T 4 (F 1,38 = 4.64, P = 0.04; Fig. 4 ) but not for T 3 (F 1,38 = 0.11, P = 0.74; data not shown). A subsequent ANCOVA adjusting for pre-OVX treatment phase values demonstrated the presence of a significant effect of diet on T 4 (F 1,38 = 7.25, P G 0.01; Fig. 4 ) but not on T 3 (F 1,38 = 1.70, P = 0.20). Ovariectomy, diet, or their interaction had no significant effects on TSH (Ovariectomy: F 1,37 = 1.80, P = 0.19; Diet: F 1,37 = 0.76, P = 0.39; Ovariectomy-by-Diet: F 1,37 = 1.38, P = 0.25; data not shown).
Isoflavones and thyroid function
Correlational analyses between individual and total serum isoflavones and T 3 , T 4 , and TSH concentrations under the SOY condition revealed significant positive associations between T 3 and genistein (r = 0.33, P = 0.03) and between T 3 and total serum isoflavones (r = 0.31, P G 0.05; Fig. 5 ) during the pre-OVX treatment phase. No significant associations were observed in the data collected during the post-OVX treatment phase. There were no significant associations between thyroid hormones and equol.
DISCUSSION
This study reports the results of the first preclinical experiment to evaluate the effects of dietary soy on thyroid function in a single NHP cohort treated both before and after surgical menopause. Notably, all animals consumed typical North American diets that differed only in the source of protein (high isoflavone soy vs CL). The major findings were that dietary soy increased T 3 in intact adult female monkeys and prevented a decline in T 4 after surgical menopause. In addition, ovarian function (progesterone concentration) was correlated with thyroid function (T 3 ), demonstrating for the first time a relationship between these physiologic pathways in female NHPs.
This study is unique, and these observations are compelling owing to the use of NHPs, a human-like diet, and a multiyear experimental design that studied the same animals before and after surgical menopause. The translation of data from rodent studies to human studies is limited because of species differences in thyroid function and isoflavone metabolism. Available data from human studies derive largely from cross-sectional studies and are thus correlational, and interpretation of these data is further limited by a lack of control over environmental variables that are known to influence thyroid function (eg, diet, energy intake, health status, social environment, circadian rhythm, and seasonal rhythm). In addition to the use of an appropriate model and an appropriate experimental design, a number of variables known to influence thyroid function were controlled for, including diet, physical and social characteristics of housing, light/dark cycle, and sampling timing.
In intact animals, SOY increased T 3 but not T 4 or TSH. These results differ from rodent studies that showed an increase in T 4 23,24 and from a small short-term study on premenopausal women that showed a decrease in T 3 . 31 Changes in T 3 only suggest that soy affects the conversion (by peripheral deiodinases) of T 4 into T 3 . Isoflavones have estrogenic activity, and estradiol has been shown to increase type I deiodinase activity in rodent liver. 32 The caveat is that T 3 is produced at the tissue level, and plasma levels do not represent total metabolic T 3 production. 33 In addition, a modest amount of T 3 is released directly from the thyroid gland. TSH has been shown to trigger the preferential release of T 3 from the thyroid gland in humans. 34 Although TSH did not differ significantly between the diet treatment conditions, preferential T 3 secretion represents a possible mechanism by which isoflavones increase plasma T 3 concentration.
SOY prevented the dramatic decrease in T 4 observed under the CL condition after ovariectomy. A post-OVX drop in T 4 has also been described in rodents, a response that is reversed by exogenous estradiol administration. 35, 36 Although no human studies have directly addressed the effects of surgical menopause on thyroid function, a dietary isoflavone supplementation study in oophorectomized women found alterations in free T 3 concentrations across time (increased at 6 wk and decreased at 12 wk). 37 Isoflavone studies performed in naturally postmenopausal women have not shown significant changes in thyroid hormones. 14,20,38<40 In general, these were short-term studies that were not fully controlled, and individual variations may have obscured the results. Alterations in thyroid function are dependent on an individual's normal set point. 41 In the current study, baseline measurements allowed us to demonstrate a change in thyroid function in response to dietary isoflavones.
The observed alterations in T 4 , but not in T 3 , under the SOY condition may have occurred at the thyroid or peripheral deiodinase level. In ovariectomized rats, T 3 and T 4 decreases are accompanied by reduced thyroid size and histologic evidence of thyroid hypoactivity. All are reversed by physiologic doses of estradiol. 35, 36 Isoflavones may act similarly, possibly via thyroidal ER binding. In ovariectomized sheep, an isoflavone-rich diet results in greater ER-> immunoactivity, higher concentrations of T 3 and T 4 , and morphologic changes in thyroid follicles. 42 In the periphery, isoflavones may boost free T 4 levels by decreasing TBG. More than 99% of plasma T 4 is proteinbound, with TBG being the predominant binding protein. Reduction of TBG after isoflavone administration 31 may have increased free T 4 in SOY-fed animals. Unfortunately, although TBG has been isolated in NHP species, assays have not been validated in macaques.
To our knowledge, this is the first study to demonstrate a relationship between thyroid function and ovarian function in macaques. Records from a rhesus monkey breeding colony suggest an association between hypothyroxinemia (decreased plasma T 4 ) and diminished reproductive performance. 11 In this study, T 3 , but not T 4 , concentrations were associated with progesterone. This may reflect the fact that T 3 possesses greater biological activity compared with T 4 . Thyroid hormones can influence reproductive function through their effects on gonadotropin-releasing hormone pulse generation, prolactin release, and sex hormoneYbinding globulin turnover, and by binding to thyroid hormone receptors (THRs) in the reproductive tract. 7 The human ovary 43 and the uterus of cynomolgus macaques 44 express THRs. It is possible that THRs are also present in the macaque ovary and function as they do in humans. In humans, T 3 and T 4 are present in follicular fluid, and addition of these hormones to granulosa cells has been shown to enhance progesterone production in vitro. 45 However, the relationship between thyroid function and ovarian function is complex and bidirectional, and the effect of isoflavones on thyroid function depends on ovarian status (intact vs surgical menopause).
The present study had some limitations. First, this study did not account for menstrual cycleYrelated fluctuations in thyroid function. Kaplan et al 30 reported no differences in reproductive measures (ovarian hormone profile or menstrual cyclicity) between the two diet treatment conditions in this cohort; however, thyroid samples were not collected in relation to menstrual cycle phase. This may have affected the outcomes because both estradiol and progesterone affect thyroid hormone concentrations. 46 A related study limitation was that we were unable to measure TBG, which may have been affected by isoflavone administration and may have been reflected in the diet treatment group differences in thyroid hormone concentration. The main translational limitation of this study was that women consume a variety of protein sources; our treatment diets consisted of only wheat protein and either soy or CL-derived protein. This and other dietary components may have affected dietary soyYthyroid relationships. However, in this NHP model, the effects of dietary soy do reflect many of those effects observed in premenopausal women, including reduced atherogenic plaque formation, 29 reduced ovarian aging, 47 and the absence of effects on bone mineral content. 48 Future studies might benefit from assessing histologic and morphometric changes in the thyroid gland. In addition, it is essential to analyze deiodinase activity, including type III deiodinase, which is involved in T 3 and T 4 degradation, to better understand the effects of soy isoflavones on thyroid hormone production and metabolism.
CONCLUSIONS
These observations suggest that dietary soy increases T 3 in intact female monkeys and prevents decline in T 4 after surgical menopause in NHPs. Furthermore, there is a positive correlation between ovary-derived progesterone levels and T 3 secretion. The outcomes observed in this study suggest that consumption of soy protein and isoflavones does not adversely affectVand may even preserveVthyroid function in postmenopausal women.
